Phase 3 Data: ATEV Cuts Catheter Days by 91 in Women on Dialysis
HUMA sits 24% above its 52-week low of $0.337 on light trading volume (0.3× avg).
Summary
Humacyte's V012 Phase 3 trial in female hemodialysis patients met its primary endpoint at a prespecified interim analysis of the first 80 patients: ATEV recipients averaged 220.4 catheter-free days in year one versus 129.3 for AV fistula, a 91-day gap with p<0.001. Functional access came at a median 1.7 months with the ATEV versus 5.3 months with a fistula, and access infections ran about 6 per 100 patient-years versus 23. Enrollment was stopped because the endpoint was met. The company says these results, plus two prior Phase 3 hemodialysis trials, support a supplemental BLA to expand the Symvess label to AV access, targeted for submission this quarter. That filing is the real swing factor: the stock trades near $0.42 after a Nasdaq delisting notice in July and a $36.8M Q2 loss with going-concern doubt, so a label expansion is the main path to a commercial franchise beyond the trauma indication.
At the time of this announcement, HUMA was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.8M. The 52-week trading range was $0.34 to $1.78. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.